Posted inBiotechnology
Fierce Biotech’s top 10 editor’s picks for 2024
The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace…
Posted inBiotechnology
Merck drops TIGIT asset and LAG-3 program, discontinuing several phase 3 trials
Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline…
Posted inResearch
American Society of Hematology member surveys identify barriers to improving diversity in clinical trials
A pair of assessments conducted by the American Society of Hematology (ASH) have helped identify roadblocks to improving diversity in…
Posted inMedical Technology
Boston Scientific recalls pacemakers at risk of triggering permanent safety mode
The FDA is boosting a recall effort from Boston Scientific regarding batteries potentially underpowering a number of the company’s implanted…
Posted inBiotechnology
UCB’s orchestra hits dud note: Novartis-partnered Parkinson’s asset fails phase 2
UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial. The oral…
Posted inBiotechnology
Roche mothballs another hemophilia A gene therapy under Spark amid plans to debut new hematologic asset
Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed that it’s…
Posted inBiotechnology
Candid Therapeutics unwraps three new collaborations to discover and develop T-cell engager antibodies
Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped…
Posted inBiotechnology
BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Century, Immatics
Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma,…
Posted inBiotechnology
Reviva’s antipsychotic shows promise against schizophrenia symptoms in year-long study
In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia…
Posted inMedical Technology
Fluid Biomed raises $27M for its bioabsorbable brain aneurysm stent
Fluid Biomed has raised $27 million to move forward with the development of its bioabsorbable stent designed to divert blood…